1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Mulhern, T.D.
Shaw, G.L.
Morton, C.J.
Day, A.J.
Campbell, I.D.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C9 H12 N O6 P
261.168
n
O-PHOSPHOTYROSINE
PHOSPHONOTYROSINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Structure
STRUE6
2005
0969-2126
5
1313
1323
10.1016/S0969-2126(97)00283-9
9351806
The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity.
1997
GW
Eur.Biophys.J.
EBJOE8
0997
0175-7571
24
371
Solution Studies of the Sh2 Domain from the Fyn Tyrosine Kinase: Secondary Structure, Backbone Dynamics and Protein Association
1996
10.2210/pdb1aot/pdb
pdb_00001aot
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
12299.815
FYN PROTEIN-TYROSINE KINASE
2.7.1.112
SH2 DOMAIN
C97S, C98S, C104S
1
man
polymer
1473.515
PHOSPHOTYROSYL PEPTIDE
1
nat
polymer
SRC HOMOLOGY 2 DOMAIN
no
no
SIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFE
TLQQLVQHYSERAAGLSSRLVVPSHK
SIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFE
TLQQLVQHYSERAAGLSSRLVVPSHK
F
polypeptide(L)
no
yes
EPQ(PTR)EEIPIYL
EPQYEEIPIYL
P
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
Escherichia coli
sample
BL21
LYSS
9606
Homo sapiens
CYTOPLASM
LYSS
469008
Escherichia coli BL21(DE3)
BL21 (DE3)
PRK172
Polyomavirus
sample
10626
Hamster polyomavirus
database_2
pdbx_database_related
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conn
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1998-01-14
1
1
2008-03-24
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_related.content_type
_pdbx_database_related.details
_pdbx_database_status.process_site
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.ptnr1_auth_comp_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr1_label_atom_id
_struct_conn.ptnr1_label_comp_id
_struct_conn.ptnr1_label_seq_id
_struct_conn.ptnr2_auth_comp_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_atom_id
_struct_conn.ptnr2_label_comp_id
_struct_conn.ptnr2_label_seq_id
_struct_ref_seq_dif.details
ensemble
Y
BNL
1997-07-10
REL
REL
LEAST VIOLATIONS
200
1
NOESY
DQF-COSY
TOCSY
HSQC
NOESY-HSQC
TOCSY-HSQC
CBCA(CO)NH
HCCH-TOCSY
XF-NOESY
XF-TOCSY
6.0
293
K
REFINEMENT DETAILS CAN BE FOUND IN THE JRNL CITATION ABOVE.
DYNAMICAL SIMULATED ANNEALING
BRUNGER
refinement
X-PLOR
3.1
structure solution
X-PLOR
500
Home-built
OMEGA
600
Home-built
OMEGA
750
Home-built
OMEGA
SER
1
n
1
SER
1
F
ILE
2
n
2
ILE
2
F
GLN
3
n
3
GLN
3
F
ALA
4
n
4
ALA
4
F
GLU
5
n
5
GLU
5
F
GLU
6
n
6
GLU
6
F
TRP
7
n
7
TRP
7
F
TYR
8
n
8
TYR
8
F
PHE
9
n
9
PHE
9
F
GLY
10
n
10
GLY
10
F
LYS
11
n
11
LYS
11
F
LEU
12
n
12
LEU
12
F
GLY
13
n
13
GLY
13
F
ARG
14
n
14
ARG
14
F
LYS
15
n
15
LYS
15
F
ASP
16
n
16
ASP
16
F
ALA
17
n
17
ALA
17
F
GLU
18
n
18
GLU
18
F
ARG
19
n
19
ARG
19
F
GLN
20
n
20
GLN
20
F
LEU
21
n
21
LEU
21
F
LEU
22
n
22
LEU
22
F
SER
23
n
23
SER
23
F
PHE
24
n
24
PHE
24
F
GLY
25
n
25
GLY
25
F
ASN
26
n
26
ASN
26
F
PRO
27
n
27
PRO
27
F
ARG
28
n
28
ARG
28
F
GLY
29
n
29
GLY
29
F
THR
30
n
30
THR
30
F
PHE
31
n
31
PHE
31
F
LEU
32
n
32
LEU
32
F
ILE
33
n
33
ILE
33
F
ARG
34
n
34
ARG
34
F
GLU
35
n
35
GLU
35
F
SER
36
n
36
SER
36
F
GLU
37
n
37
GLU
37
F
THR
38
n
38
THR
38
F
THR
39
n
39
THR
39
F
LYS
40
n
40
LYS
40
F
GLY
41
n
41
GLY
41
F
ALA
42
n
42
ALA
42
F
TYR
43
n
43
TYR
43
F
SER
44
n
44
SER
44
F
LEU
45
n
45
LEU
45
F
SER
46
n
46
SER
46
F
ILE
47
n
47
ILE
47
F
ARG
48
n
48
ARG
48
F
ASP
49
n
49
ASP
49
F
TRP
50
n
50
TRP
50
F
ASP
51
n
51
ASP
51
F
ASP
52
n
52
ASP
52
F
MET
53
n
53
MET
53
F
LYS
54
n
54
LYS
54
F
GLY
55
n
55
GLY
55
F
ASP
56
n
56
ASP
56
F
HIS
57
n
57
HIS
57
F
VAL
58
n
58
VAL
58
F
LYS
59
n
59
LYS
59
F
HIS
60
n
60
HIS
60
F
TYR
61
n
61
TYR
61
F
LYS
62
n
62
LYS
62
F
ILE
63
n
63
ILE
63
F
ARG
64
n
64
ARG
64
F
LYS
65
n
65
LYS
65
F
LEU
66
n
66
LEU
66
F
ASP
67
n
67
ASP
67
F
ASN
68
n
68
ASN
68
F
GLY
69
n
69
GLY
69
F
GLY
70
n
70
GLY
70
F
TYR
71
n
71
TYR
71
F
TYR
72
n
72
TYR
72
F
ILE
73
n
73
ILE
73
F
THR
74
n
74
THR
74
F
THR
75
n
75
THR
75
F
ARG
76
n
76
ARG
76
F
ALA
77
n
77
ALA
77
F
GLN
78
n
78
GLN
78
F
PHE
79
n
79
PHE
79
F
GLU
80
n
80
GLU
80
F
THR
81
n
81
THR
81
F
LEU
82
n
82
LEU
82
F
GLN
83
n
83
GLN
83
F
GLN
84
n
84
GLN
84
F
LEU
85
n
85
LEU
85
F
VAL
86
n
86
VAL
86
F
GLN
87
n
87
GLN
87
F
HIS
88
n
88
HIS
88
F
TYR
89
n
89
TYR
89
F
SER
90
n
90
SER
90
F
GLU
91
n
91
GLU
91
F
ARG
92
n
92
ARG
92
F
ALA
93
n
93
ALA
93
F
ALA
94
n
94
ALA
94
F
GLY
95
n
95
GLY
95
F
LEU
96
n
96
LEU
96
F
SER
97
n
97
SER
97
F
SER
98
n
98
SER
98
F
ARG
99
n
99
ARG
99
F
LEU
100
n
100
LEU
100
F
VAL
101
n
101
VAL
101
F
VAL
102
n
102
VAL
102
F
PRO
103
n
103
PRO
103
F
SER
104
n
104
SER
104
F
HIS
105
n
105
HIS
105
F
LYS
106
n
106
LYS
106
F
GLU
201
n
1
GLU
201
P
PRO
202
n
2
PRO
202
P
GLN
203
n
3
GLN
203
P
PTR
204
n
4
PTR
204
P
GLU
205
n
5
GLU
205
P
GLU
206
n
6
GLU
206
P
ILE
207
n
7
ILE
207
P
PRO
208
n
8
PRO
208
P
ILE
209
n
9
ILE
209
P
TYR
210
n
10
TYR
210
P
LEU
211
n
11
LEU
211
P
author_defined_assembly
2
dimeric
P
PTR
204
O-PHOSPHOTYROSINE
B
PTR
4
TYR
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
F
O
ILE
47
A
O
ILE
47
F
N
LYS
59
A
N
LYS
59
F
O
ARG
64
A
O
ARG
64
F
N
TYR
72
A
N
TYR
72
1
F
ARG
19
0.087
SIDE CHAIN
1
F
ARG
28
0.221
SIDE CHAIN
1
F
ARG
34
0.145
SIDE CHAIN
1
F
ARG
48
0.128
SIDE CHAIN
1
F
ARG
76
0.307
SIDE CHAIN
1
F
ARG
92
0.288
SIDE CHAIN
1
F
ARG
99
0.202
SIDE CHAIN
1
F
ILE
2
-54.56
-167.89
1
F
ALA
4
44.55
26.97
1
F
GLU
5
-179.53
41.13
1
F
GLU
6
-162.31
-69.08
1
F
LYS
11
-105.44
69.30
1
F
PHE
24
57.68
110.71
1
F
PRO
27
-78.14
-159.14
1
F
ARG
34
177.58
158.71
1
F
ASP
52
-85.10
44.22
1
F
MET
53
-161.80
20.41
1
F
LYS
54
-174.73
-29.63
1
F
LYS
59
-104.22
-166.62
1
F
ALA
94
93.19
-20.16
1
F
LEU
100
-49.02
-175.23
1
F
PRO
103
-78.03
-159.92
1
P
PRO
208
-78.20
-169.97
1
P
ILE
209
-175.48
31.16
model building
X-PLOR
3.1
refinement
X-PLOR
3.1
phasing
X-PLOR
3.1
NMR STRUCTURE OF THE FYN SH2 DOMAIN COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE, MINIMIZED AVERAGE STRUCTURE
1
N
N
2
N
N
F
ARG
14
A
ARG
14
HELX_P
F
LEU
22
A
LEU
22
1
1
9
F
LEU
82
A
LEU
82
HELX_P
F
TYR
89
A
TYR
89
1
2
8
covale
1.305
both
P
GLN
203
B
C
GLN
3
1_555
P
PTR
204
B
N
PTR
4
1_555
covale
1.305
both
P
PTR
204
B
C
PTR
4
1_555
P
GLU
205
B
N
GLU
5
1_555
COMPLEX (PROTO-ONCOGENE/EARLY PROTEIN)
SH2 DOMAIN, SIGNAL TRANSDUCTION, PEPTIDE COMPLEX, COMPLEX (PROTO-ONCOGENE-EARLY PROTEIN), COMPLEX (PROTO-ONCOGENE-EARLY PROTEIN) complex
FYN_HUMAN
UNP
1
142
P06241
TAMI_POVHA
UNP
2
321
P03079
142
247
1AOT
1
106
P06241
F
1
1
106
321
331
1AOT
201
211
P03079
P
2
1
11
1
CYS
engineered mutation
SER
97
1AOT
F
P06241
UNP
238
97
1
CYS
engineered mutation
SER
98
1AOT
F
P06241
UNP
239
98
1
CYS
engineered mutation
SER
104
1AOT
F
P06241
UNP
245
104
2
2
anti-parallel
anti-parallel
F
SER
46
A
SER
46
F
ARG
48
A
ARG
48
F
VAL
58
A
VAL
58
F
HIS
60
A
HIS
60
F
ARG
64
A
ARG
64
F
LEU
66
A
LEU
66
F
GLY
70
A
GLY
70
F
TYR
72
A
TYR
72
PHOSPHOTYROSINE BINDING SITE.
Unknown
7
+3 ILE BINDING SITE.
Unknown
5
F
ARG
34
A
ARG
34
7
1_555
F
SER
36
A
SER
36
7
1_555
F
THR
38
A
THR
38
7
1_555
F
SER
44
A
SER
44
7
1_555
F
HIS
60
A
HIS
60
7
1_555
F
TYR
61
A
TYR
61
7
1_555
F
LYS
62
A
LYS
62
7
1_555
F
TYR
61
A
TYR
61
5
1_555
F
ILE
73
A
ILE
73
5
1_555
F
THR
74
A
THR
74
5
1_555
F
GLY
95
A
GLY
95
5
1_555
F
LEU
96
A
LEU
96
5
1_555
1
P 1